This study reveals that the remodeling of GAM phenotypes results from the alteration of tumoral cholesterol homeostasis via IDH mutation‐induced PERK activation, highlighting PERK as a promising therapeutic target for the treatment of glioma. Here, IDH1 is linked to central nervous system cancer.